Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I StudyDeborah M Stephens, Ying Huang, Amy S Ruppert, et al.
British Journal of Haematology|June 28, 2019
Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.
Blood|January 24, 2018
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideKoichi Takahashi, Boyu Hu, Feng Wang, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 28, 2026
Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin LymphomaDaniel Ermann, Victoria Vardell, Erin Zacholski, et al.
British Journal of Haematology|March 30, 2019
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatmentsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 26, 2025
Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131Andrea C Lo, Sarah A Milgrom, Raymond Mailhot Vega, et al.
Blood Advances|August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohortJackson T Bowers, Jacob Anna, Steven M Bair, et al.
Haematologica|April 27, 2023
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomesCharlotte B Wagner, Ken Boucher, Adrienne Nedved, et al.
The Lancet. Oncology|December 1, 2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studySwaminathan P Iyer, R Alejandro Sica, P Joy Ho, et al.
Haematologica|November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centersViktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Pageof 7